Czech, Julia <br/><br/>
JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation.  [electronic resource] 

 -  Leukemia  04 2019 
 - 995-1010 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/s41375-018-0295-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Animals<br/>Antiviral Agents--pharmacology<br/>Apoptosis<br/>Biomarkers, Tumor--genetics<br/>Calreticulin--genetics<br/>Cell Proliferation<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Interferon-alpha--pharmacology<br/>Janus Kinase 1--genetics<br/>Janus Kinase 2--genetics<br/>Male<br/>Mice<br/>Middle Aged<br/>Mutation<br/>Myeloproliferative Disorders--drug therapy<br/>Prognosis<br/>Retrospective Studies<br/>STAT1 Transcription Factor--genetics<br/>Tumor Cells, Cultured